OverviewSuggest Edit

Trovagene is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is an orally bioavailable, which has explored in preclinical antitumor activity as a single agent and in synergy combinations with approximately 10 different chemotherapeutics and targeted therapies.

TypePublic
Founded1999
HQSan Diego, US
Websitetrovagene.com
Employee Ratings2.3

Latest Updates

Employees (est.) (Feb 2019)12(-29%)
Revenue (FY, 2018)$378.3 K(-25%)
Share Price (May 2019)$3.2 (+2%)

TrovaGene Office Locations

TrovaGene has an office in San Diego
San Diego, US (HQ)
11055 Flintkote Ave Suite B
Show all (1)

TrovaGene Financials and Metrics

TrovaGene Revenue

TrovaGene's revenue was reported to be $378.33 k in FY, 2018
USD

Revenue (FY, 2018)

378.3k

Gross profit (FY, 2018)

(219.1k)

Gross profit margin (FY, 2018), %

(57.9%)

Net income (FY, 2018)

(16.5m)

EBIT (FY, 2018)

(17.1m)

Market capitalization (16-May-2019)

16.6m

Closing stock price (16-May-2019)

3.2

Cash (31-Dec-2018)

11.5m
TrovaGene's current market capitalization is $16.6 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

259.2k280.2k312.8k381.1k505.4k378.3k

Revenue growth, %

(90%)12%22%

Cost of goods sold

15.4k629.2k1.7m1.8m597.5k

Gross profit

264.7k(316.4k)(1.3m)(1.3m)(219.1k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

43.8k111.0k55.6k57.2k127.0k49.3k57.3k120.5k103.4k89.1k95.0k102.0k123.3k100.1k111.8k88.4k

Cost of goods sold

176.4k80.0k173.5k309.3k409.5k424.6k616.4k338.2k473.2k366.3k204.4k26.7k

Gross profit

(49.5k)(30.7k)(116.2k)(188.8k)(306.1k)(335.4k)(521.4k)(236.2k)(349.9k)(266.2k)(92.6k)61.7k

Gross profit Margin, %

(39%)(62%)(203%)(157%)(296%)(376%)(549%)(232%)(284%)(266%)(83%)70%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

25.8m27.3m67.5m13.9m8.2m11.5m

Accounts Receivable

79.0k56.7k98.7k100.5k77.1k

Inventories

Current Assets

26.1m27.7m68.4m39.0m9.5m12.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

27.8m22.9m34.7m31.2m44.0m41.3m74.1m60.0m22.6m22.6m10.2m7.8m7.4m6.7m18.5m15.1m

Accounts Receivable

69.6k129.3k59.9k62.4k59.4k99.7k67.0k61.9k158.5k85.2k80.3k157.4k178.1k

Current Assets

28.0m23.3m35.0m31.6m44.5m41.9m74.8m60.9m51.6m48.0m29.7m8.7m8.6m7.8m19.6m16.0m

PP&E

740.3k859.6k817.0k841.4k1.0m1.4m1.8m4.7m4.7m4.7m3.6m3.3m3.1m2.2m1.8m1.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(11.8m)(14.3m)(27.5m)(39.2m)(24.9m)(16.5m)

Depreciation and Amortization

130.5k234.8k378.7k1.1m1.2m859.5k

Inventories

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(10.8m)(3.2m)(4.3m)(9.6m)(17.4m)(20.1m)(10.3m)(20.5m)(30.7m)(10.0m)(18.0m)(22.3m)(4.8m)(8.5m)(12.3m)

Depreciation and Amortization

85.5k53.5k111.3k169.6k153.0k250.6k156.8k489.7k693.5k331.0k646.0k957.0k252.5k483.5k701.8k

Accounts Payable

379.7k461.8k484.7k1.1m1.1m1.3m1.1m925.2k968.4k

Cash From Operating Activities

(5.5m)(2.8m)(5.5m)(8.9m)(10.2m)(15.3m)(6.9m)(15.0m)(22.0m)(8.8m)(13.4m)(19.9m)(2.9m)(6.1m)(9.6m)
USDY, 2018

Revenue/Employee

22.3k

Financial Leverage

1.4 x
Show all financial metrics

TrovaGene Online and Social Media Presence

Embed Graph

TrovaGene News and Updates

Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib

SAN DIEGO, April 5, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today...

Thinking about buying stock in Canopy Growth Co., Goldcorp Inc., Seelos Therapeutics Inc., Tonix Pharma Corp., or Trovagene Inc.?

NEW YORK, March 8, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, GG, SEEL, TNXP, and TROV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Trovagene Announces Fourth Quarter and Full-Year 2018 Results

SAN DIEGO, March 6, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today...

Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC at ASCO-GU Conference

SAN DIEGO, Feb. 14, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today...

Trovagene Announces Adjournment of Special Meeting of Stockholders Until February 12, 2019

SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers,...

TrovaGene Blogs

Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price from Institutional Investor, Lincoln Park Capital

Additional funding further extends runway for Trovagene to accelerate clinical development of onvansertib for the treatment of cancers where new therapeutic options are most needed

Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML

Data provides support for clinical evaluation of onvansertib in combination with venetoclax in patients with difficult-to-treat relapsed or refractory acute myeloid leukemia (AML)

Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital

Investment follows recent receipt of ~$3.2 million from exercise of previously issued warrants

Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy

Early PSA response observed when onvansertib is added to abiraterone (Zytiga®) in 2 of 6 patients to-date; first patient achieves primary efficacy endpoint

Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels

Greatest anti-leukemic activity has been observed in the onvansertib + decitabine arm, with complete response in 2 of 4 (50%) of evaluable patients from the two highest dose levels
Show more

TrovaGene Frequently Asked Questions

  • When was TrovaGene founded?

    TrovaGene was founded in 1999.

  • How many employees does TrovaGene have?

    TrovaGene has 12 employees.

  • What is TrovaGene revenue?

    Latest TrovaGene annual revenue is $378.3 k.

  • What is TrovaGene revenue per employee?

    Latest TrovaGene revenue per employee is $31.5 k.

  • Who are TrovaGene competitors?

    Competitors of TrovaGene include MiracleCord, Evox Therapeutics and Crossbeta Biosciences.

  • Where is TrovaGene headquarters?

    TrovaGene headquarters is located at 11055 Flintkote Ave Suite B, San Diego.

  • Where are TrovaGene offices?

    TrovaGene has an office in San Diego.

  • How many offices does TrovaGene have?

    TrovaGene has 1 office.